A correlative biomarker study and integrative prognostic model in chemotherapy-naïve metastatic castration-resistant prostate cancer treated with enzalutamide.
María P Fernandez-PerezEnrique Perez-NavarroTeresa Alonso GordoaVincenza ConteducaAlbert FontSergio Vázquez-EstévezAránzazu González-Del-AlbaDaniel WetterskogEmmanuel S AntonarakisBegona MelladoOvidio Fernandez-CalvoMaría J Méndez-VidalMiguel A ClimentIgnacio DuranEnrique GallardoAngel Rodriguez SanchezCarmen SantanderMaria I SáezJavier PuenteJulian TudelaAlberto MartínezMaria J López-AndreoJosé PadillaRebeca LozanoDavid HervasJun LuoUgo de GiorgiDaniel CastellanoGerhardt AttardEnrique GrandeEnrique Gonzalez-BillalabeitiaPublished in: The Prostate (2022)
TMPRSS2-ERG detection did not correlate with differential activity of enzalutamide in first-line mCRPC. However, we observed that CTCs and plasma AR gain were the most relevant biomarkers.